4/2
09:00 am
sabs
SAB Biotherapeutics (SABS) is now covered by Rodman & Renshaw. They set a "buy" rating and a $13.00 price target on the stock.
Low
Report
SAB Biotherapeutics (SABS) is now covered by Rodman & Renshaw. They set a "buy" rating and a $13.00 price target on the stock.
3/19
04:55 pm
sabs
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/19
04:01 pm
sabs
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
3/17
10:46 pm
sabs
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
3/17
04:43 pm
sabs
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/17
04:15 pm
sabs
SAB Biotherapeutics announces public stock offering; shares down [Seeking Alpha]
Medium
Report
SAB Biotherapeutics announces public stock offering; shares down [Seeking Alpha]
3/17
04:01 pm
sabs
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
3/14
06:59 am
sabs
SAB Biotherapeutics (SABS) was downgraded by Zacks Research from "hold" to "strong sell".
Medium
Report
SAB Biotherapeutics (SABS) was downgraded by Zacks Research from "hold" to "strong sell".
3/14
01:32 am
sabs
Medium
Report
3/11
03:02 pm
sabs
SAB Biotherapeutics (SABS) had its price target raised by Chardan Capital from $12.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (SABS) had its price target raised by Chardan Capital from $12.00 to $14.00. They now have a "buy" rating on the stock.
3/10
08:03 am
sabs
SAB Biotherapeutics (SABS) had its price target lowered by HC Wainwright from $9.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
SAB Biotherapeutics (SABS) had its price target lowered by HC Wainwright from $9.00 to $7.00. They now have a "buy" rating on the stock.
3/10
07:42 am
sabs
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes [Yahoo! Finance]
Medium
Report
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes [Yahoo! Finance]
3/10
07:31 am
sabs
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Medium
Report
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
3/9
05:59 pm
sabs
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Medium
Report
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
3/9
05:16 pm
sabs
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Medium
Report
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
3/2
09:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences
3/2
12:12 am
sabs
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf [Yahoo! Finance]
Low
Report
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf [Yahoo! Finance]
2/4
09:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences